Stergios A Polyzos1, Dimitrios G Goulis2, Olga Giouleme3, Georgios S Germanidis4, Antonis Goulas5. 1. First Laboratory of Pharmacology, School of Medicine, Campus of Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. spolyzos@auth.gr. 2. Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. 3. 2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. 4. 1st Department of Internal Medicine, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. 5. First Laboratory of Pharmacology, School of Medicine, Campus of Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
Abstract
PURPOSE OF REVIEW: Obesity is closely associated with nonalcoholic fatty liver disease (NAFLD), a highly prevalent disease without any approved medication. The aim of this review was to summarize the evidence on the effect of anti-obesity medications on NAFLD, especially focusing on hepatic histology. RECENT FINDINGS: Orlistat and some glucagon-like peptide-1 receptor analogs, including liraglutide and semaglutide, have beneficial effects on hepatic steatosis and inflammation, but not fibrosis. Other anti-obesity medications, including lorcaserin, setmelanotide, phentermine hydrochloric, phentermine/topiramate, and naltrexone/bupropion, have been minimally investigated in NAFLD. Furthermore, medications like sodium-glucose cotransporter-2 inhibitors and farnesoid X receptor have shown beneficial effects in both NAFLD and obesity, but they have not been licensed for either disease. Liraglutide, semaglutide, and orlistat may be currently used in selected patients with obesity and NAFLD. Further research is warranted, since targeting obesity may provide additional benefits on its comorbidities, including NAFLD.
PURPOSE OF REVIEW: Obesity is closely associated with nonalcoholic fatty liver disease (NAFLD), a highly prevalent disease without any approved medication. The aim of this review was to summarize the evidence on the effect of anti-obesity medications on NAFLD, especially focusing on hepatic histology. RECENT FINDINGS: Orlistat and some glucagon-like peptide-1 receptor analogs, including liraglutide and semaglutide, have beneficial effects on hepatic steatosis and inflammation, but not fibrosis. Other anti-obesity medications, including lorcaserin, setmelanotide, phentermine hydrochloric, phentermine/topiramate, and naltrexone/bupropion, have been minimally investigated in NAFLD. Furthermore, medications like sodium-glucose cotransporter-2 inhibitors and farnesoid X receptor have shown beneficial effects in both NAFLD and obesity, but they have not been licensed for either disease. Liraglutide, semaglutide, and orlistat may be currently used in selected patients with obesity and NAFLD. Further research is warranted, since targeting obesity may provide additional benefits on its comorbidities, including NAFLD.
Authors: Zobair M Younossi; Maria Stepanova; Youssef Younossi; Pegah Golabi; Alita Mishra; Nila Rafiq; Linda Henry Journal: Gut Date: 2019-07-31 Impact factor: 23.059
Authors: Stergios A Polyzos; Eun Seok Kang; Emmanuel A Tsochatzis; Stergios Kechagias; Mattias Ekstedt; Stavra Xanthakos; Amedeo Lonardo; Alessandro Mantovani; Herbert Tilg; Isabelle Côté; Aldo Grefhorst; Michael W Greene; David Araujo-Vilar; Anna Alisi; Felipe Casanueva; Christos S Mantzoros Journal: Metabolism Date: 2020-10-22 Impact factor: 8.694
Authors: Mohammed Eslam; Philip N Newsome; Shiv K Sarin; Quentin M Anstee; Giovanni Targher; Manuel Romero-Gomez; Shira Zelber-Sagi; Vincent Wai-Sun Wong; Jean-François Dufour; Jörn M Schattenberg; Takumi Kawaguchi; Marco Arrese; Luca Valenti; Gamal Shiha; Claudio Tiribelli; Hannele Yki-Järvinen; Jian-Gao Fan; Henning Grønbæk; Yusuf Yilmaz; Helena Cortez-Pinto; Claudia P Oliveira; Pierre Bedossa; Leon A Adams; Ming-Hua Zheng; Yasser Fouad; Wah-Kheong Chan; Nahum Mendez-Sanchez; Sang Hoon Ahn; Laurent Castera; Elisabetta Bugianesi; Vlad Ratziu; Jacob George Journal: J Hepatol Date: 2020-04-08 Impact factor: 25.083
Authors: Gary Whitlock; Sarah Lewington; Paul Sherliker; Robert Clarke; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Rory Collins; Richard Peto Journal: Lancet Date: 2009-03-18 Impact factor: 79.321